Introduction ! Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders characterized by persistent hyperglycemia [1] and derangement in the metabolism of carbohydrates, fats, and proteins as a result of defects in insulin secretion and/or insulin action [2] . Recent data from the International Diabetes Federation (IDF) indicates that DM affects over 366 million people worldwide and this is likely to increase to 552 million or even more by the year 2030 [3] . In Africa, more than 14 million people have diabetes, accounting for about 4.3 % of adults and is responsible for about 401 276 deaths in 2012 in the region [4] . West Africa recorded the highest number of DM cases with Nigeria (3.2 million diabetics) and Côte dʼIvoire (421 023 diabetics) occupying first and second positions, respectively. In Southern Africa, South Africa tops the list (2.0 million diabetics) followed by the Democratic Republic of Congo (737 000 diabetics). Kenya was listed as the fifth country in Africa and the first from the eastern region of Africa (720 730 diabetics), while Cameroon (517 860 diabetics) recorded the highest figure from the central region. North Africa had the least number of diabetics among the African subregions with no single nation in the top ten list of African countries with DM [4] . At present, different approaches are used to control DM using modern synthetic antidiabetic drugs in addition to lifestyle modification. This includes sulphonylureas (glibenclamide), glucosidase inhibitors (acarbose), and biguanide (metformin). However, these synthetic oral hypoglycemic agents have characteristic profiles of serious side effects, which include hypoglycemia, weight gain, gastrointestinal discomfort, nausea, liver and heart failure, and diarrhea [5] in addition to being rather costly and not affordable by the majority of African populations. These limitations coupled with an exponential increase in the prevalence of DM motivate researchers to scientifically validate the folkloric use of a number of antidiabetic African medicinal plants as possible alternative therapies. This is partly because herbs and natural products form an important compo-Abstract ! Diabetes mellitus is one of the major health problems in Africa. The conventional oral synthetic antidiabetic drugs available to manage the disease are costly and not readily affordable to the majority of the affected population. Interestingly, the continent is endowed with a tremendous number of medicinal plants that have been explored for their folkloric treatment of diabetes mellitus. Scientific investigations have validated the antidiabetic potentials of a number of these medicinal plants but there is no repository with information on these scientifically investigated plants as a guide for future research. In this review article, all of the in vivo antidiabetic studies conducted between January 2000 and July 2013 on African plants are systematically compiled with a closer look at some relevant plants from the continentʼs subregions. Plants of the Asteraceae and Lamiaceae families are the most investigated, and West Africa has the highest number of investigated plants. Although promising results were reported in many cases, unfortunately, only a few studies reported the partial characterization of bioactive principles and/or mechanisms of action. It is hoped that government agencies, pharmaceutical industries, and the scientific community will have a look at some of these plants for future research and, if possible, subsequent commercialization.
African Medicinal Plants with Antidiabetic Potentials: A Review nent of the health care delivery system in African countries [6] . According to the World Health Organization (WHO) [7] , 80 % of the population in many African countries depend almost entirely on traditional medicines, herbal medicines in particular, for their primary health care needs [8, 9] . This is attributed to the perceived effectiveness of the plant-based therapies as well as the availability of these medicinal plants because the continent accounts for about 25 % of the total number of higher plants in the world where more than 5400 medicinal plants were reported to have over 16 300 medicinal uses [10] . In Africa, herbal medicines are usually provided by a traditional healer, who utilizes natural products in curing many diseases. They have different local methods to diagnose DM in their patients, as they do not rely on laboratory investigations. This is achieved through identifying symptoms like frequent urination, sexual dysfunction, swollen legs, hands and stomach, obesity, fatigue, and profuse sweating during the consultation process. In some cases, they direct the patients to urinate on locally prepared formulations and return after a couple of days with the results of a diagnosis. At present, DM is among the diseases which are most extensively treated with traditional medicines using medicinal plants. This is evident by the propensity of the ethnobotanical surveys for medicinal plants used for the management of DM from different African subregions that include West [11, 12] , East [13] [14] [15] , North [16] [17] [18] , Southern [19, 20] , and Central Africa [21] . Interestingly, scientific investigations have confirmed the efficacy of a number of these plant-derived formulations on DM, but presently there is no comprehensive review and/or repository that exists in the literature of these scientifically investigated African antidiabetic medicinal plants that cover the whole of Africa. In this article, we conducted an exhaustive review of all scientifically investigated African antidiabetic medicinal plants whose results have been published between January 2000 and July 2013. The scientific community, government agencies, and pharmaceutical industries may use this as a possible guide for future research.
Results and Discussion
! A map of Africa indicating the subregions of the continent as used in this review is presented in l " Fig. 1 . A total of 185 plants species from 75 families in Africa have been investigated for antidiabetic effects. The information obtained on these plants includes scientific and common names, families, parts of the plant used, solvent used, and whether the crude extracts or fractions were used in the course of investigation. From the results, plants from the West African subregion account for 51.69 % of all the plants investigated for antidiabetic potentials in Africa over the period mentioned (l " Fig. 2 ). More than 90 % of all documented plants from this region emanate from Nigeria, with few data from Ghana, Senegal, Benin, Togo, and Côte dʼIvoire (l " Table 1 ). Reports on the antidiabetic effects of North African plants account for 21.91 % (l " Fig. 2 ) and originated from Morocco, Egypt, Algeria, Tunisia, Sudan, and Libya (l " Table 3 ). On the other hand, 12.92 % of antidiabetic African plants were reported from Southern Africa (l " Fig. 2 ) with most of the studies originating from South Africa (l " Table 4 ). The remaining parts, East (l " Table 2 ) and Central (l " Table 5 ) Africa, recorded 7.87 and 5.61 %, respectively, of African medicinal plants with antidiabetic effects. The results also indicated that plants from the Asteraceae and Lamiaceae families received a lot of attention in all parts of Africa (l " Fig. 3 ). On the other hand, analysis of the investigated parts of the plant indicated that the leaf was the most scientifically investigated part (l " Fig. 4 ). More importantly, promising results were reported in many cases but, unfortunately, only a few studies reported detailed characterization of bioactive principles. Data available indicated that only six plants from northern and two from western regions received partial characterization of a possible active ingredient that could be responsible for their antidiabetic effects (l " Table 6 ). In order to provide a full view of the antidiabetic potentials of these African medicinal plants, the scientifically investigated medicinal plants are categorized into subregions (l " Fig. 1 ) and discussed more thoroughly. The discussions are based on the subregions and the criteria used for highlighting a plant that has potency of the reported antidiabetic activity, except in the case of [191, 192] Leptedenia hastate Pers.
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West Africa
Anacardium occidentale L. (Anacardiaceae), or cashew, is perhaps one of the most cited plants from West Africa. The antidiabetic activity of a stem-bark methanol extract was investigated in a fructose-fed type 2 diabetes (T2D) model of rats [22] . Treatment with 200 mg/kg body weight (bw)/day of the extract given orally significantly ameliorated the changes in plasma glucose, lipid profile, malonyldialdehyde, urea, and creatinine induced by an enriched fructose diet, but showed no effect on plasma alkaline phosphatase levels. Extract treatment reduced plasma glucose levels by almost 40 % in fructose-fed type 2 diabetic rats. In another study, oral administration of an ethanolic extract of inner bark and fractions at various doses administered caused a significant decrease in blood glucose levels in a type 1 diabetes (T1D) model of rats [23] . [25] reported that administration of a methanolic leaf extract at a dose of 300 mg/kg bw recovered the beta cell damage in a T1D model of rats. Although an extensive antidiabetic study on this plant is yet to be done, the preliminary data indicates that the stem bark contains more therapeutically active antidiabetic phytochemicals than the other parts of the plant.
Another highly cited antidiabetic plant is Azadirachta indica A. Juss. (Meliaceae), which is commonly referred to as neem tree. The hypoglycemic and antihyperglycemic effects of the leaves in a T1D model of rats have been investigated [26, 27] . Oral treatment of the aqueous extract at 400 mg/kg bw/day was found to decrease fasting blood glucose by 54 % compared to the control. Further studies were conducted by Akinlola et al. [28] , who reported that the ethanolic extract orally administered at 500 mg/ kg bw/day prevented intestinal lesions and decreased hyperglycemia (87.5 %) in an STZ-induced T1D model of rats. Moreover, in 2010, Akinlola et al. [29] evaluated the chronic treatment of diabetic rats with an A. indica leaf ethanolic extract at 500 mg/kg bw/day orally on blood glucose, pancreatic islet histopathology, and oxidative status of the pancreas. The results obtained were quite promising, the fasting blood glucose of the extract-treated group dropped to 50 %, the number of β-cells was improved and, similarly, islet histology showed a marked improvement with a significant decrease in oxidative stress. In 2011, this research group also indicated that the oral administration of A. indica leaf extract at 500 mg/kg bw/day ameliorated the renal damage in an STZ-induced T1D model of rats [30] . In another study, an orally administered ethanolic leaf extract at 400 mg/kg bw/day was reported to decrease fasting blood glucose by 50 % and further prevented the alterations posed by DM on immunological and hematological parameters [31] which have clinical significance in the control of atherosclerosis and other diabetes-associated vascular complications.
Gongronema latifolium Benth. (Asclepiadaceae) is another plant that received much attention as a hypoglycemic and antihyperglycemic agent in Africa. Almost all of its parts are claimed to have an antidiabetic effect. Treatment with the aqueous leaf extract at various dosages was found to decrease the fasting blood glucose in an STZ-induced T1D model of rats [32] [33] [34] [35] . Fasting blood glucose dropped by 30.4 % compared to untreated diabetic animals. Akah et al. [36] reported that treatment with both aque- [274] ous and methanolic extracts and fractions at 800 mg/kg bw showed a significant antihyperglycemic effect in an experimentally-induced T1D model of rats. The highest glycemic reduction recorded was 43 % at 32 h post-treatment of the crude aqueous extract compared to 35% for the methanolic extract. The methanolic fraction showed the highest decrease in glycemia (30%) at 400 mg/kg bw after 32 hours of treatment. Furthermore, these extracts showed a protective effect on the activity of some cardiac enzymes, which are crucial in the management of DM, in the same model of diabetic rats [37] . In an attempt to investigate the possible mechanism of action, Adebajo et al. [38] reported the insulinotropic and glucose lowering effects of the combined root and stem bark methanolic extracts (1 : 1) and various fractions when administered orally at a dose of 100 mg/kg bw/day. It was observed that the effect of the combined extracts was far better than the individual actions of the fractions. Both the extract and fractions caused an insulin release and lowered the blood glucose levels better than glibenclimide in glucose-loaded rats and INS-1 cell lines. In another study, oral administration of ethanolic roots and twig extracts at 200 and 400 mg/kg bw/day showed a protective effect against alterations on the markers of kidney functions in a T1D model of rats [39] . Fasting blood glucose dropped by more than 60 % for a single twig administered via orogastric intubation compared to 43 % for the root ethanolic extracts. The hypoglycemic and hypolipidemic effects of Hibiscus sabdariffa L. (Malaceae) calyces have been reported [40] . The authors showed that the oral administration of the aqueous extract at 0.5 mg/ml/day alleviated the oxidative stress in a T1D model of rats [41] , which is comparable to vitamin C and glibenclimide. The extract decreased fasting blood glucose by almost 70%, which is comparable to ascorbic acid and glibenclimide. To investigate the possible mode of action, Adedayo and Ganiyu [42] revealed that the extract inhibited the activities of the two key enzymes involved in carbohydrate digestion, alpha glucosidase and alpha amylase, which are very crucial in the management of T2D mellitus.
Using an alloxan-induced T1D rat model, Tanko et al. [43, 44] demonstrated the glucose lowering effect of the hydromethanolic extract of the Indigofera pulchra L. (Papilionaceae) leaf when administered orally at 250, 500, and 1000 mg/kg bw/day. Surprisingly, the lower dosage that was administered decreased the glucose levels by 50% after 8 hours post-treatment. The daily intraperitoneal administration of ethyl acetate and n-butanol fractions of this extract also showed a hypoglycemic effect [45, 46] and was able to restore the DM-induced hematological alterations. Nauclea latifolia S. M. (Rubiaceae) is among the most widely used traditional plants in the management of DM in the different parts of Nigeria. In an attempt to investigate this claim by traditional herbalists, Gidado et al. [47] showed that the oral treatment of the aqueous leaf extract of N. [48] and were able to inhibit maltase and sucrase activities in vitro but not in vivo [49] . Other researchers reported that stem and root ethanolic extracts administered intraperitoneally at 25 mg/kg bw/day have potent immunosuppressive effects on T cell proliferation in an STZ-induced T1D model of rats [50] and could improve the antioxidant status and hormonal changes in another diabetes rat model [51] .
Ocimum gratissimum L. (Lamiaceae) is used widely as a condiment or spice in different cultural settings in Africa. It is traditionally used for the management of DM [52] . Intraperitoneal administration of 400 mg/kg bw/day of O. gratissimum methanolic leaf extract significantly decreased the blood glucose level in both normal and T1D models of rats by 56 % and 69 %, respectively [53, 54] . Oral treatments at 500, 1000, and 1500 mg/kg bw/day of the aqueous leaf extract dropped the fasting blood glucose by more than 50 % [55] . Mohammed et al. [56] also showed that the administration of 500 mg/kg bw of this extract caused a reduction in blood glucose by 81.3 % 24 hours after administration. Moreover, the O. gratissimum leaf ethanolic extract treated at 200 mg/ kg bw/day prevented the alteration of germinal epithelium, distortion of seminiferous tubules, as well as vacuolation of seminiferous tubules in an STZ-induced T1D model of rats [57, 58] . More recently, Oguanobi et al. [59] reported that oral administration of the O. gratissimum leaf extract at 100, 200, and 300 mg/kg bw/ day had a blood glucose lowering effect and the ability to alleviate derangements in serum and biliary bilirubin, cholesterol, and electrolytes in a neonatal STZ-induced T2D rat model [60] . Phyllanthus amarus L. (Euphorbiaceae) (stone breaker or gulf flower) is another highly cited antidiabetic plant from West Africa. The hypoglycemic potential of the aqueous leaf extract of P. amarus was investigated in an alloxan-induced T1D rat model. Ziziphus spina-christi
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Rhamnaceae Leaf/butanol fraction Chritinin-A Egypt [112] [113] [114] after 15 days of oral administration. Aqueous leaf and seed extracts at 150, 300, and 600 mg/kg bw/day were also shown to have antihyperglycemic, antihyperlipidemic, and cardioprotective effects as well as an insulin sensitizing effect in a T2D model of rats [64] . The hypoglycemic effect of the seed aqueous extract of Picralima nitida Stapf. (Apocynaceae) has been investigated in a T1D model of rats [65] . The extract at 648 mg/kg bw decreased the fasting blood glucose by about 19.46 % and 75.5 % in normoglycemic and alloxanized rats within 3 and 6 hours, respectively. However, a contradictory finding was reported by Igboasoiyi et al. [66] where the seed (250 mg/kg bw/day), but not fruit pulp, extract showed no hypoglycemic effect. The folkloric use of Vernonia amygdalina Del. (Compositae) (bitter leaf) in the management of DM is widely documented and this corroborates with the propensity of antidiabetic studies conducted in both type 1 and type 2 animal models of diabetes [67] [68] [69] [70] [71] [72] [73] [74] and human subjects [75] . In all studies reported, V. amygdalina was found to significantly reduce the hyperglycemia in T1D models of rats. The alterations on the markers of kidney functions were prevented by the leaf ethanolic extract administered at 400 mg/kg bw/day by gastric intubation and the fasting blood glucose was decreased by more than 80 % [76] . Oral administration of this extract was also reported to prevent the macrovascular complications associated with DM [77] . In an attempt to further investigate the hypoglycemic effect of this plant, Akah et al. [78] reported that the hexane/ethyl acetate fraction obtained from the leaf methanolic extract possessed an antidiabetic effect when treated orally at 80, 160, and 320 mg/kg bw/day. The histological and hematological results showed no alterations on the full tissue architecture and other parameters analyzed. It was also reported that V. amygdalina leaf ethanolic extract at 100 mg/ kg bw/day prevented the alteration of germinal epithelium, distortion of seminiferous tubules, as well as vacuolation of seminiferous tubules in an STZ-induced T1D model of rats [58] . The synergistic or antagonistic effects of this plant with other traditionally claimed antidiabetic plants have also been documented in numerous studies [79] [80] [81] [82] .
Another plant that has received much attention from researchers and has been used in the management of DM is Zingiber officinale L. (Zingiberaceae) (ginger). Its hypoglycemic effect has been reported in STZ and glucose-induced diabetic rat models [83] [84] [85] . The glucose-lowering effect began after 30 minutes of intraperitoneal administration of a rhizome aqueous extract at 2, 4, and 8 mg/kg bw. At 200, 250, and 300 mg/kg bw, the decreases in the blood glucose levels were recorded as 51.4 %, 56.9 %, and 56.7 %, respectively. In another study, Iranloye et al. [86] investigated the antihyperglycemic and antioxidant effects of an orally administered aqueous extract of Z. officinale at 500 mg/kg bw/day in both type 1 and fructose-fed T2D models of rats. The extracts decreased blood glucose by 48.23 % in type 1, and 83.5 % in T2D models of rats. The extract also showed the high radical scavenging ability and improvement of insulin biosynthesis in this experiment. It has also been reported that Z. officinale at doses of 250 and 500 mg/kg bw/day could inhibit oxidative stress and inflammation by enhancing antioxidant enzymes and TNF-α activity in an STZ-induced T1D model of rats [87] . Arikawe et al. [88] , in their studies, indicated that this extract could prevent the diabetes and insulin resistant-associated effects on spermatogenesis in an experimentally induced diabetes rat model.
North Africa
Ajuga iva L. (Labiatae) is among the most frequently investigated antidiabetic plants from northern Africa, especially Morocco and Algeria. The hypoglycemic and hypolipidemic effects of the aqueous extract of A. iva have been investigated in a number of T1D models of rats [89] [90] [91] . Oral administration of the extract at 10 mg/kg bw/day reduced the plasma glucose levels by 69.73 % after a 6-hour post-treatment period and 87.3 % in a subchronic dosing of 28 days in diabetic rats compared to 21.4 % and 18.4 % in normoglycemic rats, respectively. Furthermore, the in vivo antioxidant effects of this plantʼs extracts have also been reported in an STZ-induced T1D model of rats [92] . The 4-week supplementation of 0.5 % aqueous extract of A. iva prevented oxidative damages by decreasing lipid peroxidation, and improved the activities of plasma and tissue antioxidant enzymes in experimentally induced diabetic rats. Hamden et al. [93] reported that the phytoecdysteroids rich extract of A. iva prevented the diabetes-associated microvascular complications in alloxan-induced diabetic rats when administered orally for fifteen days. Allium cepa L. (Liliaceae) (onion) is widely distributed throughout the African region and is among the most cited plants from West and North Africa. The antidiabetic effect of A. cepa was evaluated in both animal models and human subjects [94] . Fresh crude slices (100 g) of A. cepa were given to type 1 and 2 diabetic human subjects. In type 1 diabetic subjects, a 50 % reduction in the blood glucose level was observed at 4 hours post-treatment compared to insulin-treated (70.8 %) patients. In type 2 diabetic subjects, about 20 % reduction was observed compared to 37.5 % in insulin-injected subjects [94] . It was also reported by El-Demerdash et al. [95] that A. cepa at a dose of 1 mL or 0.4 g/100 g bw restored the biochemical and antioxidant status altered by alloxan injection in a T1D model of rats. The concentration of thiobarbituric acid reactive substances and the activity of glutathione S-transferase in plasma, liver, testes, brain, and kidneys were significantly increased in alloxan diabetic rats. These increases were completely prevented in A. cepa-treated rats. Various compounds were isolated and correlated positively as being responsible for the hypoglycemic effect of A. cepa. Phenolics and sulphur compounds, such as cysteine and allyl propyldisulphide, have been associated with this effect [94] . Some studies linked the observed hypoglycemic effects of this plant to the essential oils [96] . In Egyptian traditional medicine, Balanites aegyptiaca L. (Balanitaceae) is popularly used as an oral hypoglycemic agent. The protective effect of orally treated aqueous and ethanolic extracts at 80 mg/kg bw/day against liver damage, and hypoglycemic and hypolipidemic effects in alloxan-induced type 1 diabetic rats were investigated [97] . Liver glycogen, serum insulin, leptin, and testosterone levels were increased in treated rats while glucagon, total lipids, total cholesterol, triglyceride level, and transaminase activities were significantly decreased. In another study, oral administration of B. aegyptiaca fruit aqueous extract at 1500 mg/kg bw/day decreased fasting blood glucose by 24% compared to the diabetic control. The dose-dependent inhibition of alpha amylase and glucose-6-phosphatase activities with an increase in glucose-6-phosphate dehydrogenase and phospho-fructokinase activities were reported [98] . The TLC and HPLC fingerprints of this extract led to the identification of a marker compound, diosgenin [98] . It has been reported that Carum carvi L. (Apiaceae) has been used for medicinal purposes since ancient times [99] . Hypoglycemic and hypolipidemic effects of the aqueous fruit extract orally administered at 20 mg/kg bw/day have been evaluated in an STZ-in-duced T1D model of rats [100, 101] . The extract significantly decreased the blood glucose levels by more than 50 % compared to nondiabetic rats within two weeks of administration but did not increase the insulin levels of normal rats. Moreover, treatment with the extract significantly decreased the serum lipid profile levels. C. carvi has been classified as a good hypoglycemic agent with high radical scavenging activity [102] . Some of the active compounds isolated from this plant include d-limonene, benzyl alcohol, o-cresol, isomenthone, methyl chavicol, d-carvone, perillaldehyde, and β-patchoullene [102] . In Morocco, Chamaemelum nobile L. (Asteraceae) is used locally for the treatment of DM and its complications. The antihyperglycemic effect of the aqueous fruit extract administered at 20 mg/ kg bw/day has been reported in an obese T2D model of mice [103] . The postprandial hyperglycemia dropped significantly by more than 80 %, and the increase in body weight was completely prevented in mice treated with this extract. In another study, Lemhadri et al. [104] reported that the extract-treated animals demonstrated a decrease in endogenous glucose production compared to the diabetic control group. It also improved insulin sensitivity in peripheral tissues, which was confirmed by an increased glucose utilization in an STZ-induced diabetic model of mice [104] .
Morus alba L. (Moraceae) (white mulberry) is another important plant used in the management of DM in northern Africa. The hypoglycemic effect of root bark flavonoid-rich fractions has been investigated [105] . The blood glucose levels of treated animals at 600 mg/kg bw for ten days dropped by about 50% compared to that of the diabetic control group. Insulin levels were significantly increased, while the peroxide levels were significantly decreased in this study. Morusin, cyclomorusin, neocyclomorusin, kuwanon E, 2-arylbenzofuran, moracinM, betulinic acid, and methylursolate were the compounds isolated from M. alba. El-Sayyad et al. [106] investigated the effect of the M. alba leaf extract on both micro-and macrovascular complications associated with DM. In their study, treatment with the extract at 100 mg/kg bw/day prevented the increase in maternal serum glucose, alterations in lipid profiles, and creatine phosphokinase activity, as well as retinal neurotransmitters including acetylcholine, adrenaline, noradrenaline, serotonin, histamine, dopamine, and gamma amino butyric acid. Furthermore, cataract and retinopathy were also prevented in the treated groups. In another study, mulberroside A, 5,7,2′-trihydroxyflavonone-4-O-β-D-glucoside, and albanols A and B were also isolated from fractions derived from the ethanolic root bark of M. alba [107] . The authors also indicated that oral administration of these fractions at 500 mg/kg bw/day significantly prevented the oxidative damage induced by hyperlipidemia in rats. Nigella sativa L. (Ranunculaceae), popularly used as a spice, has also been reported to be used traditionally in the treatment of diabetes and was investigated in a number of studies [108] . The hypoglycemic potentials of N. sativa oil from the seed have been reported [109] . The oil significantly reduced the blood glucose levels in an STZ-induced T1D model of rats within six weeks of oral administration. It was reported by the authors that the blood glucose lowering effect might be stimulated by extra hepatic tissues rather than by insulin release. In another study, N. sativa seed extract decreased the blood glucose levels by almost 81 % and normalized fructosamine, hemoglobin, and albumin levels in experimentally induced diabetic animals within 30 days of oral administration of 300 mg/kg bw [110] . The extract was able to ameliorate the diabetes-associated oxidative damages in the same study. The regulation of hepatic glycolytic and gluconeogenic enzyme activities were considered as a possible mode of action in this study. Benhaddou-Andaloussi et al. [111] have recently demonstrated the antidiabetic effect of N. sativa seed ethanolic extract when administered at 2 g/kg bw/day, and which is mediated through an insulin-sensitizing action by enhancing acetyl-CoA carboxylase phosphorylation, a major component of the insulin-independent AMPK signaling pathway, and by enhancing muscle GLUT4 expression. The antidiabetic effect of the butanol leaf extract and christinin A (a major saponin glycoside) of Ziziphus spina-christi L. (Rhamnaceae) has been investigated in both type 1 and type 2 diabetic models of rats [112, 113] . In type 2 but not in the T1D model, pretreatment of both the extract and the isolated compound at 100 mg/kg bw/day indicated a clear improvement in the oral glucose tolerance test and mediated glucose-induced insulin release. Both the extract and christin A caused a significant decrease in blood glucose levels by 24% and 22 %, respectively, after 60 minutes, and increased serum insulin levels in a T2D model of rats.
The extract was also reported to cause no damage to the kidneys, liver, or hematological parameters after 30 days of oral administration. Michel et al. [114] have also demonstrated the hypoglycemic effect of Z. spina-christi leaf ethanolic extract when fed orally at 200 mg/kg bw/day. A significant increase in serum insulin and C-peptide levels were observed in extract-treated animals. The extract also ameliorated the oxidative damages and prevented the protein glycosylation induced by diabetes. The activities of liver glucose-6-phosphatase and alpha amylase (IC 50 of 0.3 mg/mL) were inhibited by this extract, but significantly increased the activity of glucose 6-phosphate dehydrogenase. HPLC and spectrophotometric determination revealed a flavonoid as a marker compound named christinin A in this plant.
Southern Africa
Artemisia afra Jacq. (Asteraceae) is mostly identified by its aromatic odor. It is widely available and is being used to treat DM. In 2011, Afolayan and Sunmonu [115] reported that the orally administered aqueous leaf extract at 50 and 100 mg/kg bw/day significantly decreased the blood glucose levels by more than 50 % compared to the diabetic control, with a concomitant increase in insulin levels. The extract also showed a high antioxidant effect by increasing the levels of antioxidant enzymes and decreasing lipid peroxidation. Similar effects of the extract on antioxidant defense systems in the liver and kidneys were also observed within three weeks of oral administration at the same doses in diabetic animals [116] . Bryophyllum pinnatum Lam. (Crassulaceae), popularly known as "good luck" or "life plant" is widely used in the management of DM by the majority of the African populace. Ojewole [117] has reported the antidiabetic, antinociceptive, and anti-inflammatory effects of B. pinnatum in rats using fresh egg albumin-induced pedal (paw) edema, and in an STZ-induced T1D model of rats. B. pinnatum leaf aqueous extract treated orally at 400 mg/ kg bw significantly and dose-dependently decreased fasting blood glucose in diabetic rats by almost 50 % within 8 hours. A similar effect was observed in albumin-induced acute inflammation of the rat hind paw. Raphia gentiliana De Wild. (Arecaceae) is one of the most popular plants used in the treatment of several disease ailments in the Democratic Republic of Congo. Its fruits are commonly consumed as food. The hypoglycemic effect of the aqueous fruit extract has been investigated in normoglycemic human subjects and glu-cose-induced hyperglycemic animals [118] . After one and two hours post-treatment at 200 mg/kg bw, the fasting blood glucose dropped by 27 % and 56%, respectively, in diabetic mice. In human subjects, the glycemic index (signifying glucose absorbed into the blood after a meal) and load index (total glucose content in normal subjects) recorded were − 3.60 % and − 1.36 %, respectively, which are within the recommended range. The results indicate the preventive role of R. gentiliana fruit in glucose absorption, which could be associated with the active principles present in the fruit extract. The stem bark, roots, and leaves of Sclerocarya birrea A. Rich. Hochst. (Anacardiaceae) are widely used in South Africa and African countries as folk medicine in the treatment DM. The hypoglycemic effect of the stem bark aqueous extract has been investigated in normal and STZ-induced diabetic rats [119, 120] . S. birrea stem bark aqueous extract at 800 mg/kg bw significantly and dose-dependently decreased the fasting blood glucose in both normal and diabetic-treated rats, with a maximum reduction capacity of 50.16 %, which was comparable with that of chlorpropamide (62.44 %) after 8 hours post-oral treatment. Furthermore, Musabayane et al. [121] previously established the beneficial effect of the S. birrea stem bark aqueous extract treated orally at various doses (60, 120, and 240 mg/kg bw) on markers of kidney and cardiovascular functions in diabetic rats. It significantly decreased the blood glucose levels and the levels of Na + and K + ion excretion rates, which were not altered by short-term or prolonged exposure to the extract. The same research group reported that the ethanolic stem bark extract at the same dosages improved blood glucose, the glomerular filtration rate, and mean arterial blood pressure in an STZ-induced T1D model of rats [122] . Sutherlandia frutescens R. BR., variety incana E. MEY., (Fabaceae) is among the most common and widely used plants in the southern part of Africa for the treatment of DM and its associated complications. The hypoglycemic effect of S. frutescens has been investigated [123] . The shoots aqueous extract significantly prevented the STZ-induced hyperglycemic condition in mice when administered orally at various dosages (50-800 mg/kg bw). In another study, Chadwick et al. [124] reported that S. frutescens is a potential agent in the management of DM, especially type 2 DM. The aqueous leaf extract-treated rats showed an increase in glucose uptake and utilization by peripheral tissues with a decrease in intestinal glucose absorption. Glucose uptake was carried out using [ 3 H] deoxy-glucose. The [ 3 H] deoxy-glucose count increased significantly in muscle and epididymal fat tissues when treated with the S. frutescens shoot aqueous extract in a diet-induced T2D model of rats, and the results were comparable with metformin-treated rats. In a different study, S. frutescens prevented insulin resistance and showed a hypolipidemic effect in diabetic rats [125] . The plasma free fatty acid dropped significantly. Similarly, the homeostatic model assessment (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) demonstrated that oral treatment of the extract at 50 mg/kg bw prevented the development of insulin resistance in a high-fat dietfed insulin-resistance model of rats.
Central Africa
Bersama engleriana (Melianthaceae) is commonly available in almost all African regions and has been traditionally used in the management of DM. To evaluate such a claim, preliminary hypoglycemic effects of both aqueous and methanolic leaf extracts at 300 and 600 mg/kg bw/day were reported in normoglycemic rats [126] . At the 600 mg dose, blood glucose levels dropped by 37. [131] have reported that the aqueous-ethanol extract significantly, but not dose-dependently, decreased the blood glucose levels of diet-induced type 2 diabetic rats within six hours and four weeks of oral treatment at 200 mg/kg bw/day. The percentage of decrease recorded after four weeks was 52%. The diabetic-treated rats also showed an improvement in insulin sensitivity, a decrease in body weight, and reduced water intake. In another study, Fondjo et al. [132] investigated the antidyslipidemic and antioxidant effects of K. crenata whole plant methanolic extract in an STZ-induced T1D model of rats. The extract treated orally at 50 and 68 mg/kg bw/ day showed a decrease in serum, liver, and kidney malondialdehyde levels, with an increase in activities of antioxidant enzymes. The glycemic reduction in treated animals was 35 % and 44 % for 50 and 68 mg/kg bw, respectively, after the 6-week post-treat-ment period. All diabetic-treated animals showed a decrease in lipid parameters, with an increase in HDL cholesterol levels and an overall reduction of the atherogenic index by 31%.
East Africa
Caylusea abyssinica Fresen. Fisch. & Mey. (Resedaceae) is popularly used in different East African countries for the management of DM, especially in Ethiopian folklore medicine. Tamiru et al. [133] reported the hypoglycemic effect of the methanolic leaf extract of C. abyssinica in a normal, glucose-loaded, and STZ-induced T1D model of rats when administered orally at 100, 200, and 300 mg/kg bw. In an oral glucose tolerance test, the extracttreated rats indicated a better glucose handling ability than the diabetic controls. A reduction of 52. All the extracts showed a significant and dose-dependent blood glucose lowering activity within the 4-h posttreatment period at 50, 100, and 150 mg/kg bw. The hypoglycemic effect of C. edulis was much better compared to others when given at a dose of 150 mg/kg bw and was as effective as insulin. Polyphenols were the major active components detected in the various parts of the plants under this study. Based on the toxicity study conducted for various parts of these plants, at higher dosages, aqueous extracts from the stem bark of E. abyssinica, the root bark of C. edulis, and B. pilosa leaves were nephrotoxic as well as hepatotoxic. S. henningsii leaves were moderately toxic while A. pluriseta root bark was reported as safe during these studies.
Momordica charantia L. (Cucurbitaceae) is one of the plants commonly used as food and in therapeutic purposes by both diabetic and healthy people, and has been known in traditional medicine for its glucose-lowering action worldwide [135] . Its fruit has a distinguished bitter taste, which is more pronounced as it ripens; hence, it is named bitter melon. A study reported by Matheka et al. [136] demonstrated that the oral administration of fresh fruit juice extract of M. charantia by gastric gavage at 10 ml/kg bw decreased blood glucose levels significantly by about 30 and 10 % after 30 and 90 minutes, respectively, in a T1D model of rats.
Moringa stenopetala Baker f. (Moringaceae) is acclaimed for its glucose-lowering ability in Ethiopian traditional medicine. Nardos et al. [137] reported the antidiabetic effect of the leaf extracts and fractions of M. stenopetala in an alloxan-induced T1D model of rats. The extracts and fractions intraperitoneally administered at 300 mg/kg bw decreased blood glucose levels significantly by nearly 20% after an 8-day post-treatment period. The ethanolic extract was safe up to 5 g/kg bw. Furthermore, Toma et al. [138] demonstrated both antihyperglycemic and antihyperlipidemic effects with a daily oral administration of butanol fraction from the leaf ethanolic extract of M. stenopetala for four weeks in an alloxan-induced T1D rat model.
Conclusion
! Apart from the folkloric claims, it is evident from the above reviewed studies that Africa is blessed with an abundance of antidiabetic plants resources based on scientific findings. However, due to the variations in the scientific investigations in terms of analyzed antidiabetic parameters, doses, and durations used, it is difficult to precisely identify the plant(s) with the best reported activity, but our close analysis of the reports seem to suggest that O. gratissimum, A. occidentale, V. amygdalina, G. latifolium, A. indica, C. carvi, M. alba, and A. iva are the most active because they received much attention as is evident by numerous studies and, thus, possibly contain the most bioactive antidiabetic phytochemicals among all the plants. The methods mostly utilized for the extractions of various parts via organic solvent extractions include maceration/cold extraction, soxhlet, distillation, percolation, and sequential extraction. Moreover, it is evident that very few studies were reported to involve human subjects. Most studies used either T1D or T2D animal models. Unfortunately, perhaps due to limited research resources, most of the studies are preliminary in nature (though with promising results) and do not include detailed isolation and characterization of the bioactive compounds and/or the mechanisms of antidiabetic actions. Government agencies and/or pharmaceutical industries should support more research activities in this area in order to commercially utilize these antidiabetic medicinal plants for a solution to the continentʼs myriad of economic problems.
Methodology ! Relevant literatures were collected by searching the major scientific databases including Pubmed, ScienceDirect, Medline, and Google Scholar for medicinal plants of African origin that have been studied and investigated for their antidiabetic therapeutic potentials in vivo. Some articles were found through tracking citations from other publications or by directly accessing the jour-nalsʼ website. They were considered on the basis of the geographical region of their origin. The literature considered were those available covering the period January 2000 to July 2013. The keyword combinations for the search were antidiabetic, antihyperglycemia, hypoglycemia, medicinal plant, and Africa. Supplementary information was obtained by using another keyword combination such as plant, hypoglycemia, and Africa. A total of 313 articles were retrieved in this review, out of which 256 research articles that reported in vivo, and not in vitro, activity were selected and presented in this review. Following the search, the plants were categorized and presented based on their regional origins.
